CONNECTTWEETLINKEDINCOMMENTEMAILMORE

The Trump administration fears America has lost its ability to mass-produce the medicines and medical supplies needed to fight the coronavirus and other future pandemics. So it’s considering an executive order to bring drug and medical-supply manufacturing back to the United States.

That might sound like a good idea to many Americans. But the devil is in the details. The executive order would do virtually nothing to help Americans through the current pandemic. In fact, it would destabilize drug supply chains, making it harder to discover and distribute vaccines and treatments to sick patients. Administration officials would be wise to abandon their plan.

More: Seal caretakers seek face masks as coronavirus drains supplies

The “Buy American” executive order would force federal agencies to purchase American-made drugs and raw ingredients. It would also attempt to jumpstart the construction of new pharmaceutical manufacturing plants through a combination of regulatory relief and direct funding. According to the administration, this process could take place over a mere 30 to 40 days, and the first new drug plant would supposedly open in Virginia by late April.

That sounds great, however the timeline is unrealistic, as any drug supply chain expert can attest. It can take up to a decade and around $2 billion to build a new pharmaceutical manufacturing facility, secure all the necessary equipment and supplies, hire and train workers, and take the thousands of other steps needed to sustain such complex operations.

We look out for you, your wallet and your quality of life. Whether it’s ticket-fixing judges, police misconduct, or Little League officials’ questionable finances, we’re here for you. Consider purchasing a digital subscription to APP.com and download our mobile app today.

Even with emergency funding and regulatory waivers, it would be virtually impossible to have numerous additional drug plants up and running within months. America also lacks enough trained chemists to synthesize adequate quantities of “active pharmaceutical ingredients” — the chemicals that make up medicines.

Right now, a majority of the pills and injectable therapies that Americans take are manufactured domestically. However, about 80 percent of active pharmaceutical ingredients are produced overseas.

More: Coronavirus response: Former CDC chief gives his assessment in Q&A

History shows that these geographically diversified supply chains are a strength, not a weakness. When Hurricane Maria slammed Puerto Rico in 2017, it disrupted the operations of 50 pharmaceutical firms. But firms were able to limit drug shortages by working with the FDA to source medicines from manufacturing plants abroad — and innovative drug companies were hardly even fazed.

As former FDA commissioner Scott Gottlieb explained in a recent interview, “The branded companies that were manufacturing drugs there had very hardened facilities. They had redundant generators, they had months and months of fuel on hand, they had no disruptions in their manufacturing because their facilities were so well equipped.”

These diversified supply chains will help in the current crisis, too. It makes no sense to stop buying supplies from overseas while our own country is facing imminent, widespread shutdowns. Europe alone houses over a quarter of all API facilities that make ingredients for the U.S. market.

More: Coronavirus NJ: Ocean County test site opened with scheduled, prescribed tests

Trying to forcibly re-shore the production of drugs’ active pharmaceutical ingredients could also violate America’s obligations under the World Trade Organization agreements, inviting retaliatory actions from our trading partners. With our economy in free fall, the last thing we need right now is a trade war escalation.

Reshoring the entire supply chain would also raise the price of medicines — the exact opposite of the Trump administration’s longstanding goal. Manufacturing medical supplies and ingredients in developed markets like the United States can be up to five times costlier than doing so in India or China.

The administration’s executive order would endanger patients and alienate America’s trading partners when we need them most. In times of crisis like this, rash actions can feel satisfying — but cause great damage. Let’s hope cooler heads prevail.

Sandip Shah is founder and president of Market Access Solutions, which develops strategies to optimize patient access to life-changing therapies.

Asbury Park Press March 2020 Cartoons

Posted!

A link has been posted to your Facebook feed.

Shelter in Place

Shelter in Place Signe Wilkinson
Cheap drugs

Cheap drugs Lisa Benson
Debt

Debt Ramirez
Craps

Craps Ramirez
New York

New York Breen
Get off the beach

Get off the beach Margulies
coronavirus

coronavirus Anderson
Trump

Trump Clay Bennett, Clay Bennett, Chattanooga Times Free Press
Supply chains

Supply chains Lisa Benson
Trump

Trump Clay Bennett, Clay Bennett, Chattanooga Times Free Press
Economy

Economy Lisa Benson
politics

politics Ramirez
Coronavirus

Coronavirus Breen
Social distancing

Social distancing Clay Bennett, Clay Bennett, Chattanooga Times Free Press
Politics

Politics Ramirez
Fauci Trump

Fauci Trump Signe Wilkinson
Babysitter for Coronavirus

Babysitter for Coronavirus Signe Wilkinson
Election

Election Clay Bennett, Clay Bennett, Chattanooga Times Free Press
Homes of the Brave

Homes of the Brave Breen
Biden

Biden Ramirez
Brave new world

Brave new world Ramirez
Economy

Economy ramirez
Biden

Biden Lisa Benson
Spring break

Spring break Ramirez
Biden

Biden Ramirez
Millennials

Millennials Ramirez
Economy

Economy Lisa Benson
Roll models

Roll models Breen
Coronavirus troops

Coronavirus troops Signe Wilkinson
Coronavirus

Coronavirus Anderson
Coronavirus

Coronavirus Margulies
Coronavirus

Coronavirus Breen
Coronavirus

Coronavirus Lisa Benson
Coronavirus testing

Coronavirus testing Signe Wilkinson
Stocks

Stocks Ramirez
Coronavirus

Coronavirus Breen
Social distancing

Social distancing Clay Bennett, Clay Bennett, Chattanooga Times Free Press
Stocks

Stocks Lisa Benson
Sanders

Sanders Ramirez
Coronavirus

Coronavirus Breen
Federal Reserve virus cure

Federal Reserve virus cure Signe Wilkinson
401(k)

401(k) Clay Bennett, Clay Bennett, Chattanooga Times Free Press
Trump

Trump Breen
Coronavirus

Coronavirus Anderson
First Woman President

First Woman President Signe Wilkinson
Patronage

Patronage Margulies
Biden

Biden Lisa Benson
Coronavirus

Coronavirus Clay Bennett/Chattanooga Times Free Press
Revolution

Revolution Lisa Benson
Schumer Supreme Court

Schumer Supreme Court Signe Wilkinson
Coronavirus

Coronavirus Breen
Biden

Biden Clay Bennett, Clay Bennett, Chattanooga Times Free Press
Joe Cool Biden

Joe Cool Biden Signe Wilkinson
Bloomberg

Bloomberg Ramirez
Biden

Biden Breen
Coronavirus

Coronavirus Ramirez
Campaign spending

Campaign spending Breen
Socialist

Socialist Nick Anderson
Biden

Biden Breen
Sanders

Sanders Ramirez
Biden

Biden Lisa Benson
Small Corona Wolrd

Small Corona Wolrd Signe Wilkinson
Coronavirus Walls

Coronavirus Walls Signe Wilkinson
CONNECTTWEETLINKEDINCOMMENTEMAILMORE
Read or Share this story: https://www.app.com/story/opinion/columnists/2020/03/30/dont-disrupt-medical-supply-chain-midst-pandemic/5088320002/

Original Source

Previous post:

Next post: